Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance

Respiratory Investigation

Volumn 52, Issue 6, 2014, Pages 330-338

  Toyokawa, Gouji ^a   Seto, Takashi ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

ALK inhibitors; Anaplastic lymphoma kinase; Non small cell lung cancer; Oncogenic drivers

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ASP 3026; CERITINIB; CRIZOTINIB; DOCETAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; X 396; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; CARBAZOLE DERIVATIVE; CELL CYCLE PROTEIN; EML4 PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SERINE PROTEINASE; SULFONE;

ALK GENE; BRADYCARDIA; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EMBRYOTOXICITY; FATIGUE; GENE ACTIVATION; GENE DOSAGE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPOPHOSPHATEMIA; INTERSTITIAL LUNG DISEASE; LYMPHOCYTOPENIA; NAUSEA; NON SMALL CELL LUNG CANCER; ONCOGENE; PNEUMONIA; QT PROLONGATION; RASH; REVIEW; SCLEROSING CHOLANGITIS; TOXIC HEPATITIS; TUMOR BLEEDING; VISUAL DISORDER; VOMITING; AGE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION; GENE FUSION; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PHYSIOLOGY; SMOKING;

AGE FACTORS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; GENE FUSION; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; ONCOGENE PROTEINS, FUSION; PIPERIDINES; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERINE ENDOPEPTIDASES; SMOKING; SULFONES;

EID: 84912576223     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2014.06.005     Document Type: Review

References (82)

1. Sawabata N., Asamura H., Goya T., et al. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol 2010, 5:1369-1375.
2. Reck M., Heigener D.F., Mok T., et al. Management of non-small-cell lung cancer: recent developments. Lancet 2013, 382:709-719.
3. Mitsudomi T., Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010, 277:301-308.
4. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010, 11:121-128.
6. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
7. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
8. Sequist L.V., Yang J.C., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
9. Wu Y.L., Zhou C., Hu C.P., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial. Lancet Oncol 2014, 15:213-222.
10. Suda K., Mizuuchi H., Maehara Y., et al. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 2012, 31:807-814.
11. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
12. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
13. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
14. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
15. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer-early success and future challenges. Nat Rev Clin Oncol 2012, 9:268-277.
16. Solomon B., Wilner K.D., Shaw A.T. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Phamacol Ther 2013, 95:15-23.
17. Iwahara T., Fujimoto J., Wen D., et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14:439-449.
18. Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin[U+05F3]s lymphoma. Science 1994, 263:1281-1284.
19. Bilsland J.G., Wheeldon A., Mead A., et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008, 33:685-700.
20. Souttou B., Carvalho N.B., Raulais D., et al. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogene-activated protein kinase pathway. J Biol Chem 2001, 276:9526-9531.
21. Le Beau M.M., Bitter M.A., Larson R.A., et al. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 1989, 3:866-870.
22. Griffin C.A., Hawkins A.L.K., Dvorak C., et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999, 59:2776-2780.
23. Debelenko L.V., Raimondi S.C., Daw N., et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011, 24:430-442.
24. Lipson D., Capelletti M., Yelensky R., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18:382-384.
25. Lin E., Li L., Guan Y., et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009, 7:1466-1476.
26. Chen Y., Takita J., Choi Y.L., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
27. Murugan A.K., Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011, 71:4403-4411.
28. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008, 99:2349-2556.
29. Chiarle R., Voena C., Ambrogio C., et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
30. Sasaki T., Rodig S.J., Chirieac L.R., et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
31. Heuckmann J.M., Balke-Want H., Malchers F., et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012, 18:4682-4690.
32. Takeuchi K., Choi Y.L., Togashi Y., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
33. Rikova K., Guo A., Zeng Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
34. Fang D.D., Zhang B., Gu Q., et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol 2014, 9:285-294.
35. Soda M., Isobe K., Inoue A., et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 2012, 18:5682-5689.
36. Gainor J.F., Varghese A.M., Ou S.H., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin Cancer Res 2013, 19:4273-4281.
37. Camidge D.R., Kono S.A., Flacco A., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010, 16:5581-5590.
38. Takeuchi K., Soda M., Togashi Y., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18:378-381.
39. Kim H., Park E., Kim Y.J., et al. ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement. Virchows Arch 2013, 462:597-599.
40. Toyokawa G., Taguchi K., Ohba T., et al. First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. J Thorac Oncol 2012, 7:e39-e41.
41. Toyokawa G., Takenoyama M., Taguchi K., et al. An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer 2013, 81:487-490.
42. Iwama E., Okamoto I., Harada T., et al. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014, 7:375-385.
43. Minca E.C., Portier B.P., Wang Z., et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013, 15:341-346.
44. Sholl L.M., Weremowica S., Gray S.W., et al. Cobined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013, 8:322-328.
45. Martinez P., Hernández-Losa J., Montero M.Á., et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One 2013, 8:322-328.
46. Conklin C.M., Craddock K.J., Have C., et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013, 8:45-51.
47. Park H.S., Lee J.K., Kim D.W., et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012, 77:288-292.
48. Cabillic F., Gros A., Dugay F., et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014, 9:295-306.
49. Chihara D., Suzuki R. More on crizotinib. N Engl J Med 2011, 364:776-777.
50. Christensen J.G., Zou H.Y., Arango M.E., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
51. McDermott U., Lafrate A.J., Gray N.S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
52. Cui J.J., Tran-Dubé M., Shen H., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011, 54:6342-6363.
53. Komiya T., Thomas A., Khozin S., et al. Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. J Clin Oncol 2012, 30:3425-3426.
54. Vaishnavi A., Capelletti M., Le A.T., et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013, 19:1469-1472.
55. Sakamoto H., Tsukaguchi T., Hiroshima S., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
56. Seto T., Kiura K., Nishio M., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
57. Inoue A, Nishio M, Kiura K, et al. One-year follow-up of a Phase I/II study of a highly selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC). In: Proceedings of WCLC; 2013. P3.11-034.
58. Gadgeel S, Ou SH, Chiappori AA, et al. A phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028). In: Proceedings of WCLC; 2013. Abstract16.06.
59. Marsilje T.H., Pei W., Chen B., et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in Phase 1 and Phase 2 clinical trials. J Med Chem 2013, 56:5675-5690.
60. Shaw A.T., Kim D.W., Mehra R., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-1197.
61. Friboulet L., Li N., Katayama R., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014, 4:662-673.
62. Seto T, Murakami H, Hirai F, et al. Phase I study of the ALK inhibitor LDK378 in Japanes patients with advanced, ALK-rearranged NSCLC and other tumors harboring genetic ALK alterations. In: Proceedings of WCLC; 2013. P1.11-007.
63. Rivera VM, Wang F, Anjum R, et al. AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. In: Proceedings of the 103rd AACR Annual Meeting, AACR'12. Chicago, USA; 2012.
64. Camidge D.R., Bazhenova L., Salgia R., et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol 2013, 31. (suppl; abstr 8031), http://meetinglibrary.asco.org/print/1167681.
65. Kuromitsu S., Mori M., Shimada I., et al. Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models. Mol Cancer Ther 2011, 10. (suppl; abstr A227), http://mct.aacrjournals.org/cgi/content/meeting_abstract/10/11_MeetingAbstracts/A227.
66. Lovly C.M., Heuckmann J.M., de Stanchina E., et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011, 71:4920-4931.
67. Choi Y.L., Soda M., Yamashita Y., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739.
68. Gorre M.E., Mohammed M., Ellwood K. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
69. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
70. Zhang S., Wang F., Keats J., et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011, 78:999-1005.
71. Gridelli C., Peters S., Sgambato A., et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014, 40:300-306.
72. Doebele R.C., Pilling A.B., Aisner D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
73. Maillet D., Martel-Lafay I., Arpin D., et al. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol 2013, 8:e30-e31.
74. Kaneda H., Okamoto I., Nakagawa K. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J Thorac Oncol 2013, 8:e32-e33.
75. Gainor J.F., Ou S.H., Logan J., et al. The central nervous system as a sanctuary site in ALK-positive non-small cell lung cancer. J Thorac Oncol 2013, 8:1570-1573.
76. Peled N., Zach L., Liran O., et al. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol 2013, 8:e112-e113.
77. Katayama R., Shaw A.T., Khan T.M., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17.
78. Kobayashi Y., Sakao Y., Ito S., et al. Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol 2013, 8:e75-e78.
79. Ji C., Zhang L., Cheng Y., et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther 2014, 15:570-577.
80. Katayama R., Khan T.M., Benes C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harbouring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011, 108:7535-7540.
81. Chen Z., Akbay E.A., Mikse O.R., et al. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 2014, 20:1204-1211.
82. Gouji T., Takashi S., Mitsuhiro T., et al. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?. J Thorac Oncol 2014, 9:e27-e28.